The Journal of Practical Medicine >
Advances in the mechanism and therapeutic potential of Erianin⁃induced apoptosis in breast cancer cells
Received date: 2025-04-16
Online published: 2025-07-29
This review systematically elucidates recent advances in the therapeutic application of Erianin， a natural compound derived from Dendrobium， a traditional Chinese medicine， in the treatment of breast cancer， with particular emphasis on triple-negative breast cancer （TNBC）. TNBC is characterized by the absence of estrogen receptor （ER）， progesterone receptor （PR）， and human epidermal growth factor receptor 2 （HER2） expression， which presents significant clinical challenges due to limited therapeutic targets and continued reliance on conventional chemotherapy. Erianin exhibits notable anticancer potential through the induction of apoptosis in breast cancer cells. Its primary mechanisms involve sensitizing cancer cells to apoptotic signals via activation of both intrinsic and extrinsic apoptotic pathways， particularly through mitochondrial dysfunction-mediated cytochrome c release and subsequent activation of caspase-dependent pathways. At the molecular level， Erianin effectively modulates key oncogenic signaling pathways， including PI3K/Akt， MAPK， and NFATc1 cascades， thereby suppressing cell proliferation and migration while promoting apoptosis. However， current research priorities center on investigating its synergistic effects with chemotherapeutic agents and assessing its radiosensitization potential to further enhance its clinical utility. Notably， Erianin demonstrates unique advantages in overcoming drug resistance in TNBC by modulating apoptotic regulatory networks， particularly through regulation of the Bax/Bcl-2 protein ratio， positioning it as a promising multi-target therapeutic candidate. Although existing evidence largely stems from in vitro and animal studies， future research should prioritize human clinical trials to validate its efficacy and safety， alongside pharmaceutical optimization strategies such as the development of nanodelivery systems and exploration of structural derivatives. This review systematically clarifies the core mechanism and therapeutic potential of pilanin-induced apoptosis， and provides theoretical basis for developing innovative therapeutic regimens for TNBC.
Jingshuo LI , Shoushi LIU , Hongwei. GUO . Advances in the mechanism and therapeutic potential of Erianin⁃induced apoptosis in breast cancer cells[J]. The Journal of Practical Medicine, 2025 , 41(14) : 2132 -2137 . DOI: 10.3969/j.issn.1006-5725.2025.14.002
| [1] | 王培宇， 黄祺， 王少东， 等. 《全球癌症统计数据2022》要点解读 ［J］. 中国胸心血管外科临床杂志， 2024， 31（7）： 933-954. |
| [2] | 邓雅倩， 李文肖， 徐泽林， 等. 生长方位量化联合S-Detect技术对乳腺癌腋窝淋巴结转移的预测价值 ［J］. 实用医学杂志， 2025， 41（1）： 100-107. |
| [3] | 宋子旭， 朱光正， 郭晨旭， 等. SLC35A2、前叶黄素亚基2在乳腺癌中的表达及其与临床观察指标和预后的关系 ［J］. 实用医学杂志， 2024， 40（4）： 496-502. |
| [4] | YIN L， DUAN J J， BIAN X W， et al. Triple-negative breast cancer molecular subtyping and treatment progress ［J］. Breast Cancer Res， 2020， 22（1）： 61. doi:10.1186/s13058-020-01296-5 |
| [5] | JIAO Q， WU A， SHAO G， et al. The latest progress in research on triple negative breast cancer （TNBC）： Risk factors， possible therapeutic targets and prognostic markers ［J］. J Thorac Dis， 2014， 6（9）： 1329-35. |
| [6] | 黄翠霞， 张雅倩， 杨爱萍， 等. 基于Hippo/YAP信号通路探讨穿心莲内酯抗三阴性乳腺癌的作用机制 ［J］. 实用医学杂志， 2023， 39（16）： 2050-2056. doi:10.3969/j.issn.1006-5725.2023.16.007 |
| [7] | LEON-FERRE R A， GOETZ M P. Advances in systemic therapies for triple negative breast cancer ［J］. BMJ， 2023， 381： e071674. doi:10.1136/bmj-2022-071674 |
| [8] | CETIN I， TOPCUL M. Triple negative breast cancer ［J］. Asian Pac J Cancer Prev， 2014， 15（6）： 2427-2431. doi:10.7314/apjcp.2014.15.6.2427 |
| [9] | FREMD C， JAEGER D， SCHNEEWEISS A. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer： Current knowledge and future perspectives ［J］. Expert Rev Anticancer Ther， 2019， 19（1）： 29-42. doi:10.1080/14737140.2019.1537785 |
| [10] | TONG L， YU X， WANG S， et al. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer ［J］. Breast Cancer （Dove Med Press）， 2023， 15： 647-658. doi:10.2147/bctt.s426121 |
| [11] | GARUFI G， PALAZZO A， PARIS I， et al. Neoadjuvant therapy for triple-negative breast cancer： potential predictive biomarkers of activity and efficacy of platinum chemotherapy， PARP- and immune-checkpoint-inhibitors ［J］. Expert Opin Pharmacother， 2020， 21（6）： 687-699. doi:10.1080/14656566.2020.1724957 |
| [12] | HONG J， XIE Z， YANG F， et al. Erianin suppresses proliferation and migration of cancer cells in a pyruvate carboxylase-dependent manner ［J］. Fitoterapia， 2022， 157： 105136. doi:10.1016/j.fitote.2022.105136 |
| [13] | DONG H， WANG M， CHANG C， et al. Erianin inhibits the oncogenic properties of hepatocellular carcinoma via inducing DNA damage and aberrant mitosis ［J］. Biochem Pharmacol， 2020， 182： 114266. doi:10.1016/j.bcp.2020.114266 |
| [14] | YANG Z， LIU R， QIU M， et al. The roles of ERIANIN in tumor and innate immunity and its' perspectives in immunotherapy ［J］. Front Immunol， 2023， 14： 1170754. doi:10.3389/fimmu.2023.1170754 |
| [15] | KOCOGLU S S， SE?ME M， SUNAY F B. Erianin as a Promising Novel Agent in the Treatment of Neuroblastoma： The Anticancer Effects and Underlying Molecular Mechanisms ［J］. Anticancer Agents Med Chem， 2023， 23（10）： 1204-1210. doi:10.2174/1871520623666230228095429 |
| [16] | LIU Z， HUANG L， SUN L， et al. Ecust004 Suppresses Breast Cancer Cell Growth， Invasion， and Migration via EMT Regulation ［J］. Drug Des Devel Ther， 2021， 15： 3451-3461. doi:10.2147/dddt.s309132 |
| [17] | MA L， LI M， ZHANG Y， et al. Recent advances of antitumor leading compound Erianin： Mechanisms of action and structural modification ［J］. Eur J Med Chem， 2023， 261： 115844. doi:10.1016/j.ejmech.2023.115844 |
| [18] | LI M， ZHAO Y， LI H， et al. Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology ［J］. Aging （Albany NY）， 2024， 16（3）： 2848-2865. |
| [19] | MANIAM S， MANIAM S. Small Molecules Targeting Programmed Cell Death in Breast Cancer Cells ［J］. Int J Mol Sci， 2021， 22（18）：9722. doi:10.3390/ijms22189722 |
| [20] | FU B， LOU Y， WU P， et al. Emerging role of necroptosis， pyroptosis， and ferroptosis in breast cancer： New dawn for overcoming therapy resistance ［J］. Neoplasia， 2024， 55： 101017. doi:10.1016/j.neo.2024.101017 |
| [21] | YAN L， ZHANG Z， LIU Y， et al. Anticancer Activity of Erianin： Cancer-Specific Target Prediction Based on Network Pharmacology ［J］. Front Mol Biosci， 2022， 9： 862932. doi:10.3389/fmolb.2022.862932 |
| [22] | 裴彩霞，贾楠，刘俊伶，等. 细胞死亡的多种方式及其机制研究进展［J/OL］. 解放军医学杂志，1-17［2025-04-16］.. |
| [23] | GAO J， SANA R， CALDER V， et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells： Effect of cyclosporin A ［J］. Invest Ophthalmol Vis Sci， 2013， 54（7）： 4717-4733. doi:10.1167/iovs.13-11681 |
| [24] | HU S， GAO Y， ZHOU H， et al. New insight into mitochondrial changes in vascular endothelial cells irradiated by gamma ray ［J］. Int J Radiat Biol， 2017， 93（5）： 470-476. doi:10.1080/09553002.2017.1286048 |
| [25] | 黄智超， 李国峰， 郎一帆， 等. 中药诱导肺癌细胞凋亡机制的研究进展 ［J］. 中国实验方剂学杂志， 2021， 27（23）： 226-236. |
| [26] | DAS C K， LINDER B， BONN F， et al. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells ［J］. Neoplasia， 2018， 20（3）： 263-279. doi:10.1016/j.neo.2018.01.001 |
| [27] | WEI X， LIU Q， LIU L， et al. Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway ［J］. Int J Mol Sci， 2024， 25（14）：7973. doi:10.3390/ijms25147973 |
| [28] | HUANG Y， JIAO Z， FU Y， et al. An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53 ［J］. Eur J Med Chem， 2024， 265： 116121. doi:10.1016/j.ejmech.2024.116121 |
| [29] | YAN W， ZHOU Y， YUAN X， et al. The cytotoxic natural compound erianin binds to colchicine site of β-tubulin and overcomes taxane resistance ［J］. Bioorg Chem， 2024， 150： 107569. doi:10.1016/j.bioorg.2024.107569 |
| [30] | YANG A， SUN Z， LIU R， et al. Transferrin-Conjugated Erianin-Loaded Liposomes Suppress the Growth of Liver Cancer by Modulating Oxidative Stress ［J］. Front Oncol， 2021， 11： 727605. doi:10.3389/fonc.2021.727605 |
| [31] | MEZA-SOSA K F， MIAO R， NAVARRO F， et al. SPARCLE， a p53-induced lncRNA， controls apoptosis after genotoxic stress by promoting PARP-1 cleavage ［J］. Mol Cell， 2022， 82（4）： 785-802.e10. doi:10.1016/j.molcel.2022.01.001 |
| [32] | GUO Z， LUO J， MASHL R J， et al. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models ［J］. Cancer Res Commun， 2024， 4（6）： 1430-1440. doi:10.1158/2767-9764.crc-24-0047 |
| [33] | FENG Y， WU Z， LIU H， et al. Combining photodynamic therapy and ATM inhibition using modified bovine serum albumin： A co-delivery nano platform for eliciting pyroptosis and apoptosis to fuel TNBC therapy ［J］. Int J Biol Macromol， 2025， 307（Pt 4）： 142140. doi:10.1016/j.ijbiomac.2025.142140 |
| [34] | ZHANG X， WANG Y， LI X， et al. The anti-carcinogenesis properties of erianin in the modulation of oxidative stress-mediated apoptosis and immune response in liver cancer ［J］. Aging （Albany NY）， 2019， 11（22）： 10284-10300. doi:10.18632/aging.102456 |
| [35] | KAWAMOTO Y， AYAKI T， URUSHITANI M， et al. Activated caspase-9 immunoreactivity in glial and neuronal cytoplasmic inclusions in multiple system atrophy ［J］. Neurosci Lett， 2016， 628： 207-212. doi:10.1016/j.neulet.2016.06.036 |
| [36] | 李震， 曹奕鸥， 肖立俊， 等. 毛兰素及其衍生物抗肿瘤作用研究进展 ［J］. 中成药， 2019， 41（10）： 2442-2444. |
| [37] | XIE H， FENG S， FARAG M A， et al. Synergistic cytotoxicity of erianin， a bisbenzyl in the dietetic Chinese herb Dendrobium against breast cancer cells ［J］. Food Chem Toxicol， 2021， 149： 111960. doi:10.1016/j.fct.2020.111960 |
| [38] | TANG L， RUAN Y， WANG B， et al. Erianin inhibits the progression of DDP-resistant lung adenocarcinoma by regulating the Wnt/β-catenin pathway and activating the caspase-3 for apoptosis in vitro and in vivo ［J］. Hereditas， 2024， 161（1）： 48. doi:10.1186/s41065-024-00351-x |
| [39] | LAM F， BRADSHAW T D， MAO H， et al. ZJU-6， a novel derivative of Erianin， shows potent anti-tubulin polymerisation and anti-angiogenic activities ［J］. Invest New Drugs， 2012， 30（5）： 1899-1907. doi:10.1007/s10637-011-9755-9 |
| [40] | MIAO Q， DENG W Q， LYU W Y， et al. Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS（G13D） colorectal cancer ［J］. Free Radic Biol Med， 2023， 204： 301-312. doi:10.1016/j.freeradbiomed.2023.05.008 |
| [41] | SHENG Y， CHEN Y， ZENG Z， et al. Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming ［J］. J Med Chem， 2022， 65（1）： 460-484. |
| [42] | ZHU Q， SHENG Y， LI W， et al. Erianin， a novel dibenzyl compound in Dendrobium extract， inhibits bladder cancer cell growth via the mitochondrial apoptosis and JNK pathways ［J］. Toxicol Appl Pharmacol， 2019， 371： 41-54. doi:10.1016/j.taap.2019.03.027 |
| [43] | FAN Y， HE S. The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer ［J］. Cancer Manag Res， 2022， 14： 1-17. doi:10.2147/cmar.s316700 |
| [44] | LI G， ZHANG H， LAI H， et al. Erianin： A phytoestrogen with therapeutic potential ［J］. Front Pharmacol， 2023， 14： 1197056. doi:10.3389/fphar.2023.1197056 |
| [45] | 舒波， 甘鸿川， 出良钊，等. 载药纳米递送系统在胶质瘤治疗中的研究进展 ［J］. 实用医学杂志， 2022， 38（16）： 1993-1997. |
/
| 〈 |
|
〉 |